New mRNA vaccine aims to shield against RSV
NCT ID NCT06564194
First seen Apr 23, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early-stage study tests a new mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy adults aged 18-45 and 60 or older will receive either the vaccine or a placebo. The main goals are to check for side effects and measure antibody levels over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DelRicht - New Orleans
New Orleans, Louisiana, 70115, United States
-
Health Awareness
Jupiter, Florida, 33458, United States
-
Sundance Clinical Research
St Louis, Missouri, 63131, United States
Conditions
Explore the condition pages connected to this study.